(Q33539485)

27 July 2017

1 reference

title

Cilostazol. (English)

1 reference

27 July 2017

2

A Markham

0 references

author name string

E M Sorkin

series ordinal

1

1 reference

27 July 2017

A Markham

series ordinal

2

1 reference

27 July 2017

publication date

1 January 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

14

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

63-71; discussion 72-3

1 reference

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

27 July 2017

cites work

1 reference

12 December 2020

Effect of cilostazol, a new antithrombotic drug, on cerebral circulation

1 reference

12 December 2020

The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.

1 reference

12 December 2020

Cilostazol, a cAMP Phosphodiesterase Inhibitor, Attenuates the Production of Monocyte Chemoattractant protein-1 in Response to Tumor Necrosis Factor-α in Vascular Endothelial Cells

1 reference

12 December 2020

Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells

1 reference

12 December 2020

Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle

1 reference

12 December 2020

Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography

1 reference

12 December 2020

Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study

1 reference

12 December 2020

Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women

1 reference

12 December 2020

Effect of cilostazol on platelet aggregation and experimental thrombosis

1 reference

12 December 2020

Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhdbitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo

1 reference

12 December 2020

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

1 reference

12 December 2020

Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells

1 reference

12 December 2020

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

1 reference

12 December 2020

Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol

1 reference

12 December 2020

Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities

1 reference

12 December 2020

Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers

1 reference

12 December 2020

Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.

1 reference

12 December 2020

The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.

1 reference

12 December 2020

10.2165/00002512-199914010-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1040790590

0 references

Fatcat ID

release_733myzeoxbforgh34527qyzjj4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/733myzeoxbforgh34527qyzjj4

24 November 2022

mapped directly with Wikidata item

1 reference